Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) has appointed experienced senior global pharma executive Dr Simon Green to the Board of Directors as an independent non-executive director.
This appointment adds to the significant international pharmaceutical experience of the board with Green having 30 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of life saving medicines.
He worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation prior to joining CSL in 1998.
At CSL, Green was actively involved in the company’s global expansion over a 17-year period and held roles as senior vice president, Global Plasma R&D and general manager of CSL’s manufacturing plants in Germany and Australia.
Described as “an innovator”
Pharmaxis chairman Malcolm McComas said, “We are delighted to welcome Simon to the Pharmaxis board.
"He is an innovator with a strong drive to improve the lives of patients and his deep experience in product development at CSL is very relevant to our near-term plans for the commercialisation of our drug candidates for myelofibrosis and other fibrotic diseases.”
Green’s breadth of skills covers R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organisational design.
“An exciting portfolio”
The new director said: “I look forward to contributing to the pipeline of exciting new products at Pharmaxis.
“The company has an impressive team, excellent facilities and an exciting portfolio of commercially attractive product candidates for the treatment of diseases with serious unmet medical needs.”
Melbourne, Australia-based Green was educated at Monash University (Bachelor’s Degree with Honours) and the University of Melbourne (Doctor of Philosophy, Biochemistry and Immunology). He is also a graduate of the Australian Institute of Company Directors’ company directors course.
He is a non-executive director of Clover Corporation (ASX:CLV) Limited and is the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics company.
Green, who will take up his non-executive director role on December 16, 2022, is also a venture partner and investment advisor at BioScience Managers, a healthcare investment firm, and serves on the scientific advisory board for Imunexus Pty Ltd.